Itaconix plc

H1 2025 sales were $4.8 million, up 73% versus H1 2024, and the period was a record half, 20% above the prior record in H1 2023. Gross profit was $1.7 million, with gross margin held at 35%. Adjusted EBITDA loss improved to $200,000 from $800,000 in H1 2024. Performance Ingredients revenue was $3.3 million, up 51%, with average gross margin of 45%; SPARX revenue was $1.5 million, up 156%, with average gross margin of 13%; and North America sales were $3.3 million versus Europe and global sales of $1.5 million. The company ended the period with $6.6 million of net working capital, and working capital days rose from 83 to 87 days due to inventory builds tied to tariff risk mitigation. No formal next-quarter or full-year financial guidance was provided, but management said 2025 outlook remains “very positive” and that the company is positioned well for 2026.

John Shaw framed the half-year as a major step in building Itaconix into a larger, highly profitable specialty ingredients company. He emphasized that the company has a technology platform that can support a $100 million business over time, with scale inhibitors as the main growth engine, odor neutralizers as an added opportunity, and BIO*Asterix as a longer-term 3- to 5-year growth plan. His tone was confident and constructive, while repeatedly stressing that the company is focused on near-term profitability and disciplined resource allocation.

Laura Denner focused on the financial turnaround: revenue up 73% to $4.8 million, gross profit up to $1.7 million, EBITDA loss narrowed to $200,000, and gross margin maintained at 35%. She highlighted segment economics, noting Performance Ingredients at 45% gross margin and SPARX at 13% gross margin, while saying the company continues to price to value. She also pointed to balance-sheet and operating discipline, including $6.6 million of net working capital, inventory builds that lifted working capital days from 83 to 87, and fixed-asset investment that reduced fixed asset turn from 11x to 9x but still above industry comparables.

Analysts pressed management on the path to breakeven, the realism of the $100 million revenue target, customer concentration, share-price weakness, and the usefulness of the OTC listing. Management said it is roughly one major revenue step away from profitability, that the $100 million target is achievable but timing depends in part on BIO*Asterix and broader product rollout, and that the customer base has been restructured into a more profitable, more durable mix. On shareholder concerns, Shaw said profitability should broaden investor interest, while also noting the OTC listing mainly serves U.S. holders and that investor relations efforts will focus near term on the U.K. market.